Linnea SA has partnered with the Universidade Estadual de Campinas (UniCamp), a public research university in the state of São Paulo, Brazil. This partnership aims to streamline and advance scientific development and research into cannabinoids.
The cannabinoid market in Latin America has been growing over the last few years as a result of patients' demand for safe, reliable, and effective therapy. The current cannabinoid delivery forms are often not aligned with the standards of quality typical of the pharmaceutical world and necessary to ensure the safety and efficacy for patients.
As the demand for cannabinoid therapies rises, health authorities are gradually creating rules to protect consumers and help healthcare personnel to identify the best cannabinoid treatments.
To help accelerate this process, Linnea SA and Unicamp are now working together on the development of innovative cannabinoid-based products in alignment with current and future medical needs. Linnea SA and Unicamp believe promoting science through high-quality products can help people to receive better treatments.
For more information: